Norwest Equity Partners Acquires Pentec Health - Frazier Healthcare
Norwest Equity Partners Acquires Pentec Health - Frazier Healthcare
Norwest Equity Partners Acquires Pentec Health - Frazier Healthcare
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Jason Sondell, a Director at NEP and <strong>Pentec</strong> board member, stated, “This investment is a testament to<br />
NEP’s healthcare investment strategy of partnering with profitable and growing companies with strong<br />
business models and management teams. <strong>Pentec</strong> is a world-class operation run by a best-in-class<br />
management team that has broad and deep experience leading pharmaceutical and healthcare<br />
businesses. With its unmatched capabilities, therapies, and services, <strong>Pentec</strong> is poised to continue to<br />
grow both organically through increased penetration within its growing markets, and through<br />
acquisitions of companies in both existing and adjacent markets.”<br />
Additional financing for this transaction was provided by <strong>Norwest</strong> Mezzanine <strong>Partners</strong>, Madison Capital<br />
Funding, Golub Capital, Zions Bank, and CIT Group.<br />
Simultaneous to the close of the transaction, Cosgrove assumed the role of Chairman of the Board of<br />
Directors in addition to his CEO role. <strong>Pentec</strong> employs nearly 300 people and is headquartered in<br />
Boothwyn, Pennsylvania. More information can be found on www.pentechealth.com.<br />
____________________________________________________________________________________<br />
Partnering with business owners since 1961, <strong>Norwest</strong> <strong>Equity</strong> <strong>Partners</strong> (NEP) is a leading investment firm focused on<br />
building companies into industry leaders. With a reputation for quality investments and exceptional financial<br />
returns, NEP manages $5 billion of capital through a series of equity and mezzanine funds. The firm is currently<br />
investing NEP IX, with $1.2 billion in capital.